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Background: Anti-arrhythmic drugs (AADs) are often administered following catheter ablation (CA) for
persistent atrial ﬁbrillation (peAF) to maintain sinus rhythm (SR). It remains unclear whether AADs can
be withdrawn in patients showing no recurrence after CA.
Method: We administered hybrid therapy consisting of CA and AAD (bepridil) in 75 patients with peAF.
Withdrawal of AADs was attempted in patients who had no recurrence of AF for Z6 months. We
followed them for 22716 months.
Results: Patients received 1.270.4 sessions of CA and a mean bepridil dose of 131746 mg/day. After a
3-month ‘‘blanking period,’’ 62 (83%) patients maintained SR without recurrence of tachyarrhythmia
for Z6 months. AADs were discontinued in 41 patients who agreed to medication withdrawal. Ten of
these (24%) experienced a relapse of tachycardia, and these patients had a higher incidence of residual
inducibility of tachyarrhythmia at the end of the CA procedure (70% vs. 32%; P¼0.03) and required a
higher dose of bepridil to maintain SR (170748 mg vs. 106730 mg; Po0.0001) than those without
relapse.
Conclusions: Discontinuation of AADs occasionally results in recurrence, especially in patients with
residual inducibility and in those requiring higher doses of AADs.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Recurrence of tachyarrhythmia is one of the major issues
associated with catheter ablation (CA) for atrial ﬁbrillation (AF),
and is much more common in persistent AF than in paroxysmal
AF [1,2]. Intensive ablation of the left atrium (LA) is often
performed in patients with persistent AF to correct electrical
and anatomical LA remodeling [3–5], but a substantial portion of
these patients still suffer relapse of AF. Anti-arrhythmic drugs
(AADs) are often administered after CA to maintain sinus rhythm
(SR). There have been a few studies that have examined the
efﬁcacy of AADs in patients with paroxysmal AF [6,7], but their
effect on persistent AF is almost unknown. It is also unclearrt Rhythm Society. Published by E
abashi Watanabe Hospital,
: þ81 6 6341 8651;whether AAD treatment could be terminated if no recurrence is
observed after CA. In the present study, we studied the efﬁcacy of
hybrid therapy consisting of AADs and CA against persistent AF.
We also investigated factors that would predict the successful
discontinuation of AADs.2. Methods
2.1. Study patients
We enrolled 77 consecutive patients with drug-resistant
persistent AF who received the initial CA between April 2005
and December 2007. Persistent AF was deﬁned as conﬁrmed AF
persisting for Z1 week. Exclusion criteria were as follows: age
Z80 years, LA diameter Z50 mm, persistent AF for Z10 years,
left ventricular ejection fraction o40%, sinus node dysfunction,
hepatic/renal impairment, and the lack of informed consent prior
to drug administration. We also excluded patients in whom CAlsevier B.V. All rights reserved.
Table 1
Baseline patient characteristics.
n¼75
Age (years) 6077
Height (cm) 169710
Body weight (kg) 70711
Male, n (%) 65 (87%)
Hypertension, n (%) 31 (41%)
Diabetes, n (%) 6 (8%)
Structural heart disease, n (%) 25 (33%)
Dilated cardiomyopathy 8 (11%)
Hypertrophic cardiomyopathy 2 (3%)
Ischemic heart disease 5 (7%)
Valvular disease 7 (9%)
Others 3 (4%)
Old cerebral infarction, n (%) 2 (3%)
AF history, months (median) 55740 (48)
Duration of continuous AF, months (median) 27735 (10)
Number of failed AADs (median) 1.971.2 (2)
History of bepridil prescription, n (%) 23 (31%)
LAd (Pre-CA) (mm) 41.476.1
LAd (Post-CA) (mm) 36.774.1
LVEF (%) 59711
Creatinine (mg/dL) 0.970.2
BNP (pg/mL) 147.57144.6
Follow-up period, months (median) 2478 (23)
Abbreviations: AF, atrial ﬁbrillation; AAD, anti-arrhythmic drugs; LAd, left atrial
diameter; CA, catheter ablation, LVEF, left ventricular ejection fraction; BNP, brain
natriuretic peptide.
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of the procedure, and those showing thrombi in the LA on
transesophageal echocardiography performed 1–3 day (median,
1 day) before CA.
2.2. Ablation procedure
We performed CA for persistent AF in a standard fashion. After
trans-septal access, a bolus of intravenous heparin was adminis-
tered to maintain an activated clotting time of 4250 s. Two spiral
catheters were placed within the ipsilateral superior or inferior
pulmonary vein (PV). Patients were sedated during the procedure.
We performed cardioversion at the beginning of the procedure,
and CA was performed in SR if restoration of SR was possible.
The radiofrequency was delivered at a maximum output of 35 W
using an 8-mm tip catheter at a target temperature of 50–55 1C.
Continuous radiofrequency lesions surrounding each ipsilateral
PV antrum were deployed until the local electrocardiogram of the
PV and the antrum disappeared or was dissociated. We performed
linear ablation connecting the contralateral PV-encircling lesion
through the LA roof in some patients. The inducibility of supra-
ventricular tachyarrhythmia was then evaluated by burst atrial
pacing (5-s bursts with an output of 20 mA) from the coronary
sinus, left atrial appendage, and right atrial free wall, beginning at
a cycle length of 200 ms and reducing by 10-ms intervals until
atrial refractoriness or a cycle length of 150 ms was achieved. If
AF was induced and persisted for 41 min, ablation to a contin-
uous fractionated atrial electrogram or linear ablation to the LA
roof and/or the mitral isthmus were performed. If re-entrant
tachyarrhythmias were induced, we attempted to identify the
isthmuses of their circuit and to ablate them. Non-PV foci of
premature atrial contractions were also ablated.
The endpoint for the procedure was no induction of supraven-
tricular tachycardia for Z1 min after burst stimulation. The
procedure time was limited to 3 h.
2.3. Administration of AADs
We selected bepridil as the AAD for hybrid therapy, and
treatment was initiated on the day of successful ablation at an
initial dose of 100 mg/day. The dose could be increased to
200 mg/day if relapse occurred. When recurrence of tachycardia
could not be prevented by bepridil, aprindine (r60 mg) [8] was
additionally administered, or another CA was performed. When
the QT duration was 500 ms or more, bepridil was discontinued
or the dose was reduced.
2.4. Follow-up
Patients were followed up at our outpatient clinic once a
month for 6 months after CA, and once every 2–3 months
thereafter. The patients were instructed to take their own pulse
at least 3 times a day, and to visit the clinic when their pulse was
irregular. We recorded an ECG at every visit regardless of
subjective symptoms. Three months after the ablation was
deﬁned as the blanking period [9]. Echocardiography was per-
formed before and 3 months after the operation to measure the
left atrial diameter. The level of brain natriuretic peptide (BNP)
was also measured before and 3 months after ablation. The
average follow-up period was 22716 months.
2.5. Withdrawal of AADs
When a patient had no relapse for Z6 months after ablation,
withdrawal of the AAD was proposed and, if the patient agreed,
the dose was reduced by half. If the reduction of AAD wassuccessful, we withdrew it completely. Subsequently, patients
were followed up for the presence or absence of arrhythmia
recurrence for an average of 1678 months.
2.6. Statistical analysis
All values are expressed as the mean7SD unless otherwise
indicated. Baseline and follow-up variables were compared using
paired t-test analysis. The unpaired t-test or analysis of variance
was used to compare variables between different patient groups.
Categorical variables were compared using chi-square analysis. A
probability value o0.05 was considered statistically signiﬁcant.3. Results
3.1. Procedural results of catheter ablation
AF was not terminated by CA and cardioversion in 2 out of 77
enrolled patients, and thus the ﬁnal study cohort consisted of 75
patients. Their baseline characteristics are presented in Table 1;
the mean disease duration of AF was 55740 months and the
mean duration of persistent AF was 27735 months. Coexisting
heart disease was found in 33% of the patients.
PV isolation was successfully performed in all 75 patients.
Linear ablation on the LA roof was performed in 69 (92%) patients,
and a block line was obtained in 67 patients. However, the
inducibility of atrial tachyarrhythmia by burst pacing remained
in 38 (51%) patients at the end of the procedure. No major
complications were observed after ablation, with the exception
of minor pericardial effusion in 1 patient. The average total
procedure time was 2.770.5 h (Table 2).
3.2. Efﬁcacy of hybrid therapy
All study patients were discharged with normal SR with
receiving bepridil. Relapse of tachycardia was observed in 36
patients (48%) out of 75 patients during the blanking period.
Table 2
Catheter ablation procedural data.
Isolated PV/Targeted, n (%) 75 (100)/75 (100)
Blockline of LA roof/Targeted, n (%) 67 (89)/68 (91)
Ablation to:
Mitral annulus isthmus, n (%) 29 (39)
Coronary sinus, n (%) 18 (24)
CFAE, n (%) 22 (29)
Origin of non-PV foci, n (%) 12 (16)
Superior vena cava, n (%) 11 (15)
Cavo-tricapsid isthmus, n (%) 22 (29)
Right atrium, n (%) 12 (16)
Remaining AF inducibility after procedure, n (%) 38 (51)
Procedure time, h (median) 2.770.5 (2.5)
Abbreviations: PV, pulmonary vein; LA, left atrium; CFAE, complex fractionated
atrial electrogram; AF, atrial ﬁbrillation.
Persistent AF (n=77)
Catheter Ablation
Sinus Conversion (n = 75) AF (n = 2)
Bepridil in all patients (average131+/-41 mg/day) and 
Aprindine <60mg/day in 6 patients
Sinus Rhythm without AF/AT (n = 54)
Sinus Rhythm (n = 8)
Re-session of Catheter Ablation (n = 12, 13 sessions)Change of AAD (n = 9)
Recurrent AF/AT (n = 21)
Persistent AF
n = 4
Sinus Rhythm
W/O Paroxysmal AF/AT
n = 62
Sinus Rhythm
W/ Paroxysmal AF/AT
n = 9
Fig. 1. Efﬁcacy of hybrid therapy.
Table 3
Characteristics of patients that failed withdrawal of anti-arrhythmic drugs.
Withdrawal of AADs p-value
Success Failure
Follow-up period (months) 21.278.4 14.6710.6 0.05
Age (years) 60.777.7 60.778.3 0.99
Male 83% 90% 0.62
Period of AF persistence (months) 28738 32740 0.77
No. of refractory AAD 1.6 70.9 1.971.1 0.83
Height (cm) 168711 169711 0.83
Weight (kg) 71.3712.5 63.7712.4 0.1
Hypertension 40% (12/31) 30% (3/10) 0.71
Diabetes mellitus 10% (3/31) 0% (0/10) 0.31
Heart failure 26% (8/31) 10% (1/10) 0.25
Serum creatinine (mg/dL) 0.9470.18 0.8770.16 0.28
BNP (pg/mL) 119.57128 126.8783 0.9
LAD (pre-CA) (mm) 42.176.3 39.275.4 0.17
LAD (post-CA) (mm) 38.273.6 3675.2
Ejection fraction (%) 61.679.8 57.7711.6 0.3
Successful PV isolation 100% (31/31) 100% (10/10) 1
Non-PV AF trigger 19% (6/31) 20% (2/10) 0.97
Ablation to:
CFAE 32% (10/31) 50% (5/10) 0.17
Coronary sinus 32% (10/31) 20% (2/10) 0.47
Superior vena cava 16% (5/31) 20% (2/10) 0.78
Right atrium 10% (3/31) 60% (6/10) 0.0005
Residual inducibility 32% (10/31) 70% (7/10) 0.04
Mean dose of bepridil (mg) 106730 170748 o0.0001
Abbreviations: AF, atrial ﬁbrillation; AAD, anti-arrhythmic drug; BNP, brain
natriuretic peptide; LAd, left atrial diameter; CA, catheter ablation, PV, pulmonary
vein; CFAE, complex fractionated atrial electrogram.
Cessation of Bepridil (n = 62) and Aprindine (n = 1)
Sinus Rhythm without Paroxysmal AF/AT (n = 62)
Agree (n = 41)
Weaning and Cessation of AAD
Disagree (n = 22)
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dine was additionally administered to 6 of these patients. After
the blanking period, 21 (28%) of these patients suffered from
recurrence. Subsequently, another CA was performed in 12
patients (13 ablations), and bepridil was replaced by other AADs
in 9 (12%) patients. The mean number of ablation sessions was
1.1770.4, and the average maximum dose of bepridil in the
study group was 131746 mg/day. Overall, 71 (95%) patients
maintained normal SR for 46 months, though 9 of them (12%)
still had paroxysmal AF. Only 4 (5%) had a recurrence of persistent
AF (Fig. 1). QT prolongation for Z500 ms was observed in
2 patients who were given 200 mg of bepridil, and the dose was
reduced to 100 mg. Bepridil was discontinued due to stomach
upset in 1 patient, who had a relapse of paroxysmal AF later. No
other major complications were observed.Sinus Rhythm (n = 8)
Sinus Rhythm
with Paroxysmal AF/AT
(n = 2)
Restart of AAD (n = 8)
or Re-session of Catheter Ablation (n = 4)
Sinus Rhythm (n = 31) Recurrent AF/AT (n = 10)
Sinus Rhythm
without Paroxysmal AF/AT
(n 37)
Persistent AF
(n = 2)
Fig. 2. Withdrawal of anti-arrhythmic drugs and relapse of tachycardia.3.3. Changes in echocardiography parameters and BNP
Echocardiography studies demonstrated a reduction in the left
atrial diameter from 41.476.1 mm to 37.774.1 mm on average
(Po0.0001) during the 3 months after ablation. The average left
ventricular ejection fraction improved from 58.8711% to
63.3710.2% (P¼0.01), and the average BNP level decreased from
147.57144.6 pg/mL to 64.67101.1 pg/mL (P¼0.002) at 3months
after the procedure.3.4. Withdrawal of AAD and relapse of tachycardia
Withdrawal of AADs was proposed to 62 (83%) patients who
had had no relapse of tachyarrhythmia for 46 months. In the 41
patients who agreed to AAD reduction and discontinuation, a
reduction in the AAD dose was initiated at a mean of 1175
months after the initial administration. Thirty-one (76%) patients
maintained normal SR in spite of the withdrawal of AADs. The 10
patients (24%) who experienced relapse had exhibited a higher
incidence of residual inducibility of tachycardia at the end of
ablation (70% vs. 32%; P¼0.03), had received higher doses of
bepridil (170748 mg vs. 106730 mg; Po0.0001), and required
right atrial ablation to maintain SR more frequently (60% vs. 10%,
K. Inoue et al. / Journal of Arrhythmia 28 (2012) 170–174 173P¼0.005) than those without relapse (Table 3). The diameter of
the LA was not associated with the successful withdrawal of AADs
(42.376.1 vs. 39.275.4 mm; P¼0.17). AADs were re-adminis-
tered in 8 of the 10 patients with relapse, and CA was performed
again in 4 patients. However, 2 patients developed persistent AF
again and 2 other patients developed paroxysmal tachyarrhyth-
mia (Fig. 2).4. Discussion
The present study had 2 aims: to elucidate the efﬁcacy of
hybrid therapy for atrial ﬁbrillation, and to investigate the
possibility of withdrawal of AADs in patients with successful
hybrid therapy. We administered bepridil (131746 mg/day)
following CA in 75 patients with persistent AF, and succeeded in
maintaining normal SR in 95% of the study subjects, with
relatively few repeated ablation sessions (average, 1.1770.4
sessions). Regarding side effects, QT prolongation was observed
in 2 patients during bepridil administration, but no ventricular
tachyarrhythmia was seen. Bepridil was subsequently withdrawn
in 41 of the 62 patients who maintained SR without any relapse of
tachycardia, and 31 (76%) patients maintained SR after the with-
drawal. Successful AAD withdrawal was associated with the
absence of right atrial ablation, the absence of residual induci-
bility of tachyarrhythmia after ablation, and the requirement for
lower doses of AAD.
4.1. Efﬁcacy of hybrid therapy using bepridil for persistent AF
Anatomical and electrical LA remodeling plays a very impor-
tant role in the persistence of AF, and extensive LA ablation is
performed in order to overcome the effects of LA remodeling
[10,11]. However, such intensive substrate ablation has several
drawbacks, such as reduced recovery from left atrial remodeling
due to the excessive loss of myocardium [12], the complexity of
the procedure, time investment, and the possibility of a higher
rate of complications. Bepridil is a unique multi-ion channel
blocker [13–16] that may reverse electrical LA remodeling
[17–19]. The J-BAF study showed that persistent AF was con-
verted to paroxysmal AF in many patients receiving bepridil, [20]
suggesting that bepridil might directly affect the substrate in the
atrium, particularly the ‘‘perpetuator.’’ Thus, bepridil might play a
similar role to extensive LA ablation in eliminating the substrate
for the persistence of AF. In spite of the high rate of SR
maintenance in this study, defragmentation and/or LA linear
ablation other than in the roof line were performed in only a
minority (42%) of the study patients.
4.2. Withdrawal of AADs
The reversal of electroanatomical LA remodeling makes it
easier to maintain SR. The maintenance of SR during the perio-
perative period is important because recurrence of AF/AT inhibits
the promotion of atrial reverse remodeling; therefore, the use of
AADs during the perioperative period might inﬂuence the long-
term efﬁcacy of CA.
On the other hand, withdrawal of AADs in the convalescent
phase might be possible in patients who maintain SR and reverse
remodeling of their atrium. Therefore, we withdrew AADs from
patients without AF relapse, and AAD withdrawal was successful
in 76% of these patients. The remaining patients who developed
relapse were more likely to have had ablation of the right atrium,
to have displayed residual inducibility of tachyarrhythmia at the
end of the procedure, and to have require 200 mg/day of bepridil
due to relapse during the blanking period. All these 3 factors arepossibly associated with the presence of residual AF substrate in
atria. These results suggest that the improvement in the AF
substrate achieved by ablation and reverse atrial remodeling
was not enough to maintain SR without AADs. In such patients,
additional substrate modiﬁcation by CA, such as linear ablation
and ablation based on the complex fractionated atrial electro-
gram, should be performed.
4.3. Appropriate dose of bepridil in this hybrid therapy
There are many reports of the effects of bepridil on AF [8,20–24],
and it is cited as one of the ﬁrst-line therapies for persistent AF in
the Japanese Guidelines of Pharmacotherapy for AF [25]. However,
the presence of severe complications such as QT prolongation and
ventricular arrhythmia have limited its widespread use [20,21], and
the dose of bepridil should be kept as low as possible to reduce the
risk of complications. In the J-BAF study, 1 patient in the 200 mg-
dose group died, probably due to ventricular arrhythmia [20]. When
combined with CA, the required dose of bepridil and the incidence of
severe complications can be reduced, and the average of maximum
dose of bepridil in the present study was 131mg, lower than that in
previous reports [8,21–24]. However, a QT prolongation (QT
Z500 ms) was still observed in 2 of 22 patients who were given
200 mg/day of bepridil, and they required dose reduction. Further-
more, the majority (77%) of patients who received 200 mg/day of
bepridil were not able to discontinue its administration because of
the recurrence of tachyarrhythmia. Therefore, we believe that
although hybrid therapy is effective against persistent AF, the
dosage of bepridil in this hybrid therapy should be 100 mg/day or
less. Patients who relapse despite the administration of 100 mg/day
of bepridil should be re-treated with CA rather than with the
addition of another AAD or an increase in the dose of bepridil.
4.4. Study limitations
We did not compare the efﬁcacy of the hybrid therapy with CA
alone or with other AADs. Thus, the present study cannot
demonstrate the superiority of the present therapy over other
regimens. It cannot be determined whether relapse after with-
drawal of bepridil was caused by the discontinuation of the AAD
or by the natural course of the disease. A prospective, randomized
control study is required to elucidate these issues. We could not
identify patients who did not require AADs to maintain SR, and
such patients were included in the bepridil 100 mg/day group.
4.5. Conclusion
Hybrid therapy comprising AADs and CA is effective in patients
with persistent AF. However, discontinuation of AADs occasion-
ally results in recurrence, particularly in patients with residual
inducibility, those who required ablation of the right atrium, and
those requiring higher doses of AADs to maintain SR.Disclosures
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